Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211458 · ClinicalTrials.gov registry record · Phase 2
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00211458: Completed Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
NCT00211458 is a Phase 2 study that has completed, run by Manhattan Eye, Ear & Throat Hospital. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211458, a Phase 2 study, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.
Interventions
- DRUG Anecortave Acetate Sterile Suspension (15 mg)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00211458 record still lists
NCT00211458 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Anecortave Acetate Sterile Suspension (15 mg) is the first listed.
NCT00211458 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00211458 about?
NCT00211458 is a clinical study titled "Treatment of Age-Related Macular Degeneration With Anecortave Acetate". The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.
What is the current status of trial NCT00211458?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00211458?
The interventions under investigation include: Anecortave Acetate Sterile Suspension (15 mg) (DRUG).
Who is sponsoring clinical trial NCT00211458?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia